Abstract

7566Background: Venetoclax (VEN) is a selective, potent oral Bcl-2 inhibitor with activity in patients (pts) with relapsed/refractory (R/R) NHL. In NHL xenograft models, VEN enhances efficacy of CH...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Results of a Phase Ib Study of Venetoclax Plus R- or G-CHOP in Patients with B-Cell Non-Hodgkin Lymphoma
Andrew D Zelenetz ... Franck Morschhauser
Blood | VOL. 128
Andrew D Zelenetz, et. al.Andrew D Zelenetz ... Franck Morschhauser
02 Dec 2016
Phase 2 Study of Venetoclax Plus Rituximab or Randomized Ven Plus Bendamustine+Rituximab (BR) Versus BR in Patients with Relapsed/Refractory Follicular Lymphoma: Interim Data
Pier Luigi Zinzani ... Wolfgang Hiddermann
Blood | VOL. 128
Pier Luigi Zinzani, et. al.Pier Luigi Zinzani ... Wolfgang Hiddermann
02 Dec 2016
Clinical Outcomes of Venetoclax Therapy in Patients with Relapsed/Refractory (r/r) Non Hodgkin Lymphomas (NHL)
Mitchell E Hughes ...
Blood | VOL. 132
Mitchell E Hughes, et. al.Mitchell E Hughes ...
29 Nov 2018
Abstract 3077: Preclinical characterization of BGB-11417, a potent and selective Bcl-2 inhibitor with superior antitumor activities in haematological tumor models
Nan Hu ...
American Journal of Cancer | VOL. 80
Nan Hu, et. al.Nan Hu ...
13 Aug 2020
View more papers

More From: Journal of Clinical Oncology

Paper Title
Journal
Date
Author
Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial.
Alexios Matikas ...
Journal of Clinical Oncology | VOL. -
Alexios Matikas, et. al.Alexios Matikas ...
17 Jul 2024
Lymphoma Classifications, How to Develop a Future Unified Taxonomy.
Elias Campo ... Reiner Siebert
Journal of Clinical Oncology | VOL. -
Elias Campo, et. al.Elias Campo ... Reiner Siebert
17 Jul 2024
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors.
Brian C Shaffer ... Monzr M Al Malki
Journal of Clinical Oncology | VOL. -
Brian C Shaffer, et. al.Brian C Shaffer ... Monzr M Al Malki
17 Jul 2024
Genetic Counseling, Testing, and Family Communication Into Survivorship After Diagnosis of Breast Cancer.
Steven J Katz ... Allison W Kurian
Journal of Clinical Oncology | VOL. -
Steven J Katz, et. al.Steven J Katz ... Allison W Kurian
15 Jul 2024
View more papers